Qinhuangdao, Hebei's HSAP Breaks Through Early Screening Challenges for Alzheimer's Disease with Original Technology
Hebei News Network (by Li Jiaxin and Wu Huanjun) - Recently, the project "Research on Early Screening, Intervention System, and Validation for Alzheimer's Disease Based on Non-invasive Brain-Computer Interface," submitted by Hebei University, has been successfully approved for the 2025 Joint R&D and Demonstration Project under the National Key R&D Program's "Strategic Science and Technology Innovation Cooperation" initiative. Qinhuangdao Huisi Anpu Medical Systems Co., Ltd. (hereinafter referred to as "Huisi Anpu"), as a core participating unit, is deeply involved in tackling key technological challenges and implementing outcomes for this national-level project. This collaboration aims to provide an original Chinese industrial solution for the early prevention and control of Alzheimer's disease (AD).
This project focuses on three core technical bottlenecks in early AD screening, precise diagnosis, and intervention therapy, aiming to overcome the limitations of traditional diagnostic and treatment models. It will pioneer a multi-modal physiological signal coupling analysis system integrating eye-brain-heart data alongside an early AD screening protocol, addressing the industry pain point of insufficient sensitivity in single-modal detection. simultaneously introducing an innovative personalized intervention paradigm integrating virtual reality neurotraining with targeted physical stimulation to establish a closed-loop "screening-diagnosis-intervention" technology chain. This aligns closely with HSAP's R&D focus in cognitive health. As the sole corporate participant, HSAP drives industry-academia-research collaboration to accelerate commercialization and clinical adoption of project outcomes.
Since its establishment in 2011, HSAP has leveraged core technologies, including bioimpedance, bionic pulse magnetic resonance, and brain-computer interfaces, to pioneer precision prevention and treatment for neurological disorders. Its independently developed ADDS Cognitive Impairment Screening System and ADTS Memory Impairment Training System have achieved nationwide clinical coverage across multiple provinces and municipalities. By integrating its mature technology products and clinical expertise into this national-level project, HSAP will contribute to optimizing multimodal screening technologies and validating personalized intervention paradigms.
"The project's approval signifies the nation's high recognition of HSAP's technological prowess and innovation capabilities," said an HSAP representative. The company will leverage this collaboration to intensify R&D investments in brain-computer interfaces and neurological disease prevention, deeply integrating cutting-edge technologies like AI and neuromodulation. This will refine its end-to-end product ecosystem spanning "screening-intervention-rehabilitation," using original technologies to address challenges in Alzheimer's prevention. The initiative aims to provide core equipment support for establishing a national cognitive health prevention network for the elderly, contributing to China's healthy aging development.